Libourne – 13 September 2018 – Fermentalg (Euronext – FALG), a French leader in microalgae for nutrition and health, releases its first half 2018 results and provides perspectives for the second half of the year.
Philippe Lavielle, Fermentalg Chairman and CEO, comments: “We have now finalised the last stages in the lead-up to the market launch of our DHA ORIGINS® range of algal oils, and we expect the first major orders to start coming in during the second half of 2018. At the same time, we are making rapid progress with the development of our protein and natural food pigment platform, particularly thanks to our partnership with the Japanese DIC Corporation Group. All of these operations have been accomplished within a tight financial framework which has allowed us to reduce cash outflow compared to first half 2017.”
Market launch of DHA ORIGINS® range
The presentation of DHA ORIGINS 550® at the 2018 Vitafoods Europe event last May confirmed the interest of major operators in the food supplement market for the first algal oil with a minimum natural DHA concentration of 550 mg/g.
Fermentalg recorded the first sales of DHA ORIGINS 550® after the qualification of marketing leads for the new product during H1 2018. However, H1 2018 revenues of €110,000 were mainly generated via an intellectual property agreement with a partner group.
Fermentalg is reasonably confident that all its marketing efforts to date will translate in sales of significant volumes of DHA ORIGINS 550® during the second half of the year.
Advances in proteins and natural pigments
Over the last few months Fermentalg achieved a notable progress in the scale up of its second technological platform for algal proteins and phycocyanin, a natural blue colourant with a strong demand in the food industry. The R&D teams successfully completed several 1,000 and 2,000 litres fermentation trials, and delivered the basic engineering studies for blue print of a semi-industrial demonstration plant, designed to test the production process in large scale and to provide the market with test quantities of material.
Given the industrial and commercial outlook for the platform, Fermentalg decided to capitalise R&D expenses incurred on projects related to this second platform as of 1 January 2018.
Meanwhile, research projects carried out in cooperation with DIC Corporation, a leading player in the Japanese chemical sector, proceeded according to plan; last January, the partners selected the second target product (confidential) alongside the previously announced thermotolerant phycocyanin.
Cash assets of €17.4 million at 30 June 2018
Strict control of company expenses has enabled the company to reduce cash outflow from €5.5 million in H1 2017 to €4.6 million in the first half of 2018. The increase in cash expenses linked to the production launch of DHA ORIGINS 500® was offset by an important reduction in administrative costs.
After inclusion of financing cash flows (€200,000 inflow during the period), gross cash and cash equivalents totalled €17.4 million at 30 June 2018 versus €21.8 million at the end of 2017. Net cash, after deduction of debt consisting of the convertible bond issue subscribed by DIC Corporation and repayable advances on development programmes, came to €9.0 million (€13.8 million at 31 December 2017) compared to shareholders' equity of €38.3 million (€41.2 million at 31 December 2017).
Publication of the first half financial report
The first half financial statements were approved by the Board of Directors on 6 September 2018 and have undergone a limited review by the statutory auditors. The financial report was made available to the public on September 13, 2018 and was filed with the French financial markets authority (AMF) on the same day. The report may be downloaded in French from the company website at https://www.fermentalg.com/en/financial-reports.html).
An expert in research and bio-industrial use of microalgae, Fermentalg seeks to provide sustainable solutions and innovative products that contribute towards the creation of natural, healthy and effective products. Our business: development, production and sale of active ingredients extracted from microalgae for the agri-food, health and nutrition sectors. Natural nutritional oils, pigments and antioxidants, as well as specialty proteins, comprise our present and future offering.
Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG).
For more information, visit: www.fermentalg.com
|Contact - Journalists:||Contact - Investors:|
|ACTUS finance & communication
Tel: +33 (0)1 53 67 36 90
|ACTUS finance & communication
Tel: +33 (0)1 53 67 36 78
Comprehensive income statement
|(€000)||H1 2018||2017||H1 2017|
|Other income from operations||906||1,103||336|
|Production and industrial deployment costs||(658)||(1,115)||(485)|
|Research and development expenses||(1,503)||(4,522)||(1,588)|
|Administrative and sales expenses||(1,386)||(2,873)||(1,619)|
|Operating income/(loss) before share-based payments and non-recurring items||(2,532)||(7,237)||(3,356)|
|Payroll expenses linked to share-based payments||(588)||(35)||(18)|
|Other non-recurring operating income and expenses||(42)||30||241|
|Operating income/(loss) after share-based payments and non-recurring items||(3,162)||(7,242)||(3,133)|
|Income from cash and cash equivalents||18||43||134|
|Gross cost of borrowings||(234)||(72)||(38)|
|Net (cost of borrowings)/income from cash and cash equivalents||(216)||(29)||96|
|Other financial income and expenses||(11)||0||(12)|
|Net tax expense||0||0||0|
|Consolidated net income/(loss)||(3,389)||(7,271)||(3,050)|
|CONSOLIDATED NET INCOME/(LOSS) (GROUP SHARE)||(3,389)||(7,269)||(3,048)|
|Items of other comprehensive income||0||0||0|
|COMPREHENSIVE CONSOLIDATED NET INCOME/(LOSS)||(3,389)||(7,271)||(3,050)|
|COMPREHENSIVE CONSOLIDATED NET INCOME (GROUP SHARE)||(3,389)||(7,269)||(3,048)|
|Consolidated net earnings per share (€)||(0.20)||(0.56)||(0.25)|
|Consolidated diluted net earnings per share (€)||(0.20)||(0.56)||(0.25)|
|Property, plant and equipment||15,949||16,511||17,245|
|Non-current financial assets||180||171||133|
|Deferred tax assets||3,236||3,236||3,236|
|TOTAL NON-CURRENT ASSETS||29,223||27,987||28,022|
|Trade receivables and other assets related to customer contracts||116||113||17|
|Cash and cash equivalents||17,373||21,752||10,248|
|TOTAL CURRENT ASSETS||21,150||26,018||13,666|
|EQUITY & LIABILITIES|
|Additional paid-in capital||42,958||52,036||40,549|
|Reserves and retained earnings||(1,929)||(4,261)||(4,388)|
|Comprehensive net income/(loss)||(3,388)||(7,269)||(3,048)|
|Shareholders' equity (Group share)||38,327||41,192||33,597|
|TOTAL SHAREHOLDERS' EQUITY||38,327||41,192||33,552|
|TOTAL NON-CURRENT LIABILITIES||8,455||8,028||3,450|
|Provisions for current risks||305||305||301|
|Other current liabilities||2,263||2,650||2,681|
|TOTAL CURRENT LIABILITIES||3,590||4,785||4,686|
|TOTAL EQUITY AND LIABILITIES||50,373||54,005||41,688|
Cash flow statement
|(€000)||H1 2018||2017||H1 2017|
|Comprehensive net income/(loss)||(3,389)||(7,271)||(3,050)|
|Depreciation, amortization and provisions (excluding provisions against current assets)||1,039||1,914||580|
|Expenses on shared-based payments||514||35||18|
|Change in deferred tax||0||0||0|
|Gains and losses on disposals||0||0||(1)|
|Gross cost of borrowings||227||62||34|
|Cash flow before cost of borrowings,
net of tax
|Change in inventories||(384)||(282)||(125)|
|Change in trade receivables||(3)||(106)||(10)|
|Change in trade payables||(895)||(1,194)||(1,492)|
|Change in other current assets and liabilities (a)||519||(321)||126|
|Change in operating working capital||(763)||(1,903)||(1,501)|
|NET CASH FLOW FROM OPERATING ACTIVITIES||(2,371)||(7,164)||(3,920)|
|Production of fixed assets (capitalised R&D)||(2,319)||(2,481)||(1,674)|
|Share of subsidies and research tax credit linked to capitalised development projects||407||430||267|
|Acquisitions of other PP&E and intangible assets||(351)||(1,091)||(483)|
|Change in fixed asset liabilities||58||(3)||340|
|Disposal of financial assets||(9)||(31)||7|
|NET CASH FLOW FROM INVESTING ACTIVITIES||(2,215)||(3,176)||(1,541)|
|Capital increase linked to parent company||0||11,688||0|
|Acquisitions and disposals of treasury shares||10||3||(3)|
|New loans and other borrowings||372||4,694||0|
|Change in current accounts||0||0||2|
|Interest paid on loans and borrowings||(175)||0||0|
|NET CASH FLOW FROM FINANCING ACTIVITIES||207||16,385||(1)|
|Change in cash and cash equivalents||(4,379)||6,045||(5,462)|
|Opening cash and cash equivalents (1)||21,752||15,708||15,708|
|Closing cash and cash equivalents (1)||17,373||21,752||10,246|
|(a): including change in research tax credit:||441||(1,153)||(500)|
(1) Cash assets less bank overdrafts
 As a consequence of the first half financial statements including the application of IFRS 15, Fermentalg transferred R&D costs passed on to collaborative project partners from revenues to ‘Other income'. This explains the difference compared to the unaudited estimated revenue figure reported on 19 July 2018.
 Net cash flow from operating activities + Net cash flow from investing activities
 Cash and cash equivalents less bank overdrafts